1,366 Shares in Repligen Co. (NASDAQ:RGEN) Purchased by iSAM Funds UK Ltd

iSAM Funds UK Ltd acquired a new position in Repligen Co. (NASDAQ:RGEN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,366 shares of the biotechnology company’s stock, valued at approximately $203,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RGEN. Tidal Investments LLC lifted its stake in Repligen by 11.6% in the first quarter. Tidal Investments LLC now owns 1,421 shares of the biotechnology company’s stock valued at $261,000 after purchasing an additional 148 shares during the last quarter. Diversified Trust Co grew its stake in shares of Repligen by 3.7% during the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock worth $372,000 after acquiring an additional 106 shares during the period. V Square Quantitative Management LLC increased its holdings in Repligen by 23.6% in the 2nd quarter. V Square Quantitative Management LLC now owns 697 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 133 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Repligen by 937.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 30,189 shares of the biotechnology company’s stock valued at $3,806,000 after acquiring an additional 27,280 shares during the period. Finally, Raymond James & Associates lifted its holdings in Repligen by 3.7% during the second quarter. Raymond James & Associates now owns 55,119 shares of the biotechnology company’s stock valued at $6,948,000 after purchasing an additional 1,951 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Wolfe Research initiated coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Finally, Wells Fargo & Company started coverage on Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $190.25.

Insider Activity at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is owned by insiders.

Repligen Stock Performance

Shares of RGEN opened at $149.20 on Monday. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a 50-day moving average price of $141.45 and a 200-day moving average price of $141.66.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.23 earnings per share. Equities analysts expect that Repligen Co. will post 1.52 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.